A Bruton tyrosine kinase (BTK) inhibitor and hematopoietic cell kinase (HCK) inhibitor are used in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.